According to expert presenters at the American Society of Preventive Cardiology’s 2025 Congress on Cardiovascular Disease Prevention, recent studies have shown significant benefit to GLP-1 inhibitors ...

Most employees said health plans should cover GLP-1 medications, with 64% saying they should and 12% saying they should not.